CAPR · As filed with the SEC
Capricor Therapeutics cash flow statement, by fiscal year
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (105,043,946) | (40,467,186) | (22,287,542) | (29,019,532) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Loss on disposal of fixed assets | 157,519 | 112,805 | 6,041 | 34,266 |
| Depreciation and amortization | 1,889,041 | 1,425,214 | 1,068,882 | 533,131 |
| Stock-based compensation | — | 9,765,164 | 7,392,396 | 4,458,578 |
| Forgiveness of debt | — | — | — | 0 |
| Stock-based compensation | 16,967,799 | — | — | — |
| Restricted stock awards granted | 257,461 | — | — | — |
| Changes in lease liabilities | 715,459 | (47,261) | (24,282) | 161,740 |
| Non-cash interest expense on CIRM liability | 3,045,725 | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Receivables | 10,309,322 | 3,504 | (9,824,413) | (155,830) |
| Prepaid expenses and other assets | (4,093,633) | (458,653) | (75,884) | 240,045 |
| Other assets | — | — | 0 | 7,550 |
| Accounts payable and accrued expenses | 5,983,992 | 1,941,136 | 1,388,078 | 1,718,312 |
| Accounts payable and accrued expenses, related party | — | — | (61,755) | (510,154) |
| Deferred revenue | 0 | (12,270,465) | (3,178,066) | 27,448,531 |
| Net cash used in operating activities | (69,811,261) | (39,995,742) | (25,596,545) | 4,916,637 |
| Cash flows from investing activities: | ||||
| Purchase of marketable securities | (151,392,398) | (208,441,162) | (97,441,506) | (114,218,737) |
| Proceeds from sales and maturities of marketable securities | 260,595,875 | 93,796,269 | 104,597,249 | 82,505,961 |
| Purchases of property and equipment | (2,904,461) | (1,166,871) | (1,311,660) | (2,000,243) |
| Payments for leasehold improvements | (383,539) | (372,104) | (735,873) | (1,359,488) |
| Payments for construction in progress | (8,436,196) | — | — | — |
| Net cash provided by (used in) investing activities | 97,479,281 | (116,183,868) | 5,108,210 | (35,072,507) |
| Cash flows from financing activities: | ||||
| Net proceeds from sale of common stock | 237,033,938 | 152,321,576 | 25,515,349 | 4,803,534 |
| Proceeds from exercise of stock awards and warrants | — | 450,173 | — | — |
| Proceeds from exercise of stock awards and warrants | 11,858,358 | — | 64,601 | 70,304 |
| Net cash provided by financing activities | 248,892,296 | 152,771,749 | 25,579,950 | 4,873,838 |
| Net increase (decrease) in cash and cash equivalents | 276,560,316 | (3,407,861) | 5,091,615 | (25,282,032) |
| Cash and cash equivalents balance at beginning of period | 11,286,996 | 14,694,857 | 9,603,242 | 34,885,274 |
| Cash and cash equivalents balance at end of period | 287,847,312 | 11,286,996 | 14,694,857 | 9,603,242 |
| Supplemental disclosures of cash flow information: | ||||
| Interest paid in cash | 0 | 0 | 0 | 0 |
| Income taxes paid in cash | 1,600 | 0 | 0 | 0 |
| Initial recognition of right-of-use asset | 13,382,191 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.